Eco R1 Capital, LLC Morphic Holding, Inc. Transaction History

Eco R1 Capital, LLC

$2.31 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$26.12 - $34.07 $67.9 Million - $88.5 Million	2,598,561 Added 108.98%	4,982,945 $170 Million
Q1 2024 May 15, 2024	BUY	$26.64 - $40.31 $57.9 Million - $87.6 Million	2,173,122 Added 1028.64%	2,384,384 $83.9 Million
Q4 2023 Feb 14, 2024	SELL	$19.95 - $31.0 $25.3 Million - $39.3 Million	-1,268,928 Reduced 85.73%	211,262 $6.1 Million
Q3 2023 Nov 14, 2023	SELL	$21.33 - $59.42 $50.5 Million - $141 Million	-2,366,774 Reduced 61.52%	1,480,190 $33.9 Million
Q2 2023 Aug 14, 2023	SELL	$34.33 - $62.11 $68 - $124	-2 Reduced -0.0%	3,846,964 $221 Million
Q1 2023 May 15, 2023	SELL	$26.01 - $48.69 $2.72 Million - $5.09 Million	-104,600 Reduced 2.65%	3,846,966 $145 Million
Q2 2021 Aug 16, 2021	BUY	$45.13 - $64.99 $43 Million - $61.9 Million	952,251 Added 31.75%	3,951,566 $227 Million
Q1 2021 May 17, 2021	BUY	$29.77 - $84.85 $4.75 Million - $13.5 Million	159,431 Added 5.61%	2,999,315 $190 Million
Q3 2020 Nov 16, 2020	BUY	$22.51 - $30.11 $43,016 - $57,540	1,911 Added 0.07%	2,839,884 $77.6 Million
Q2 2020 Aug 14, 2020	BUY	$12.65 - $29.57 $187,624 - $438,582	14,832 Added 0.53%	2,837,973 $76.8 Million
Q1 2020 May 15, 2020	BUY	$10.84 - $20.85 $7.24 Million - $13.9 Million	668,296 Added 31.01%	2,823,141 $41.4 Million
Q4 2019 Feb 14, 2020	SELL	$13.02 - $19.5 $86,908 - $130,162	-6,675 Reduced 0.31%	2,154,845 $37 Million
Q3 2019 Nov 14, 2019	SELL	$17.46 - $29.05 $1.84 Million - $3.06 Million	-105,284 Reduced 4.64%	2,161,520 $39.1 Million
Q2 2019 Aug 14, 2019	BUY	$18.0 - $19.82 $40.8 Million - $44.9 Million	2,266,804 New	2,266,804 $44.9 Million

Others Institutions Holding MORF

# of Institutions

Shares Held

4.7M

Call Options Held

Put Options Held

View Full List

About Morphic Holding, Inc.

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

More about MORF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eco R1 Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eco R1 Capital, LLC with notifications on news.

Account